By the Evernow Medical Group Updated November 13, 2020
Data from the following studies:
Women with uterus taking oral estrogen and progesterone
Women with hysterectomy taking oral estrogen
Risk increases for women without a hysterectomy and decreases for women with a hysterectomy.
9 additional cases per year per 10,000 women
7 fewer cases per year per 10,000 women
HRT prevents diabetes while taking therapy.
16 fewer cases per year per 10,000 women
21 fewer cases per year per 10,000 women
HRT prevents deaths from Alzheimer’s and dementia among women with a hysterectomy, both during and beyond therapy.
The risks were studied but no impact was detected.
80 fewer cases per year per 10,000 women
HRT (estrogen) reduces death during therapy for women with a hysterectomy.
The risks were studied but no impact was detected.
11 fewer cases per year per 10,000 women
HRT (estrogen+progestin) prevents endometrial cancer both during and beyond taking therapy for women without hysterectomy.
3 fewer cases per year per 10,000 women
Endometrial cancer is not possible with this population
HRT prevents venous thromboembolism both during and beyond therapy.
3 fewer cases per year per 10,000 women
3 fewer cases per year per 10,000 women
HRT is not associated with risk of coronary heart disease.
The risks were studied but no impact was detected.
The risks were studied but no impact was detected.
HRT (estrogen+progestin) prevents colorectal cancer during and beyond taking therapy for women without hysterectomy
7 fewer cases per year per 10,000 women
The risks were studied but no impact was detected.
HRT prevents hip fractures during therapy.
6 fewer cases per year per 10,000 women
6 fewer cases per year per 10,000 women
HRT prevents bone fractures during therapy.
51 fewer cases per year per 10,000 women
61 fewer cases per year per 10,000 women
HRT increases risk of gallbladder disease. Numbers are shown for oral HRT, but the risk is lower with transdermal HRT.**
47 additional cases per year per 10,000 women
58 additional cases per year per 10,000 women
*The study employed just one route of administration (oral), one formulation of estrogen (conjugated equine estrogens [CEE], 0.625 mg), and only one progestogen (medroxyprogesterone acetate [MPA], 2.5 mg), with limited enrollment of women with bothersome vasomotor symptoms (VMS; hot flashes, night sweats) who were aged younger than 60 years or who were fewer than 10 years from menopause onset—the group of women for whom hormone replacement therapy is primarily indicated.
** A Retrospective study of 80,396 women aged 40-79 with a primary diagnosis of venous thromboembolism (VTE), matched to 391,494 women in the control arm. The study looked for women who had been recently exposed to oral hormone replacement therapy or transdermal hormone replacement therapy to see if there was a significantly increased risk of venous thromboembolism compared with no exposure .